Education
About Us
Working with TipRanks
Follow Us
Diaceutics (GB:DXRX)
LSE:DXRX
Total Valuation
Diaceutics has a market cap or net worth of $137.02M. The enterprise value is 90.09M.
Market Cap$137.02M
Enterprise Value90.09M
Share Statistics
Diaceutics has 84,885,574 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding84,885,574
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Diaceutics’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -5.34%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-5.34%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee174.77K
Profits Per Employee-10.37K
Employee Count184
Asset Turnover0.66
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Diaceutics is ―. Diaceutics’s PEG ratio is 25.77.
PE Ratio―
PS Ratio3.30
PB Ratio2.66
Price to Fair Value2.66
Price to FCF-26.62
Price to Operating Cash Flow670.65
PEG Ratio25.77
Income Statement
In the last 12 months, Diaceutics had revenue of 32.16M and earned -1.70M in profits. Earnings per share was -0.02.
Revenue32.16M
Gross Profit28.27M
Operating Income-2.46M
Pretax Income-1.91M
Net Income-1.70M
EBITDA2.77M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was 104.00K and capital expenditures -94.00K, giving a free cash flow of 10.00K billion.
Operating Cash Flow104.00K
Free Cash Flow10.00K
Free Cash Flow per Share<0.01
Dividends & Yields
Diaceutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.61
52-Week Price Change21.43%
50-Day Moving Average149.04
200-Day Moving Average134.37
Relative Strength Index (RSI)63.39
Average Volume (3m)143.09K
Important Dates
Diaceutics upcoming earnings date is Mar 24, 2026, Before Open (Confirmed).
Last Earnings DateSep 23, 2025
Next Earnings DateMar 24, 2026
Ex-Dividend Date―
Financial Position
Diaceutics as a current ratio of 3.80, with Debt / Equity ratio of 3.05%
Current Ratio3.80
Quick Ratio3.80
Debt to Market Cap0.00
Net Debt to EBITDA-4.21
Interest Coverage Ratio-45.46
Taxes
In the past 12 months, Diaceutics has paid -205.00K in taxes.
Income Tax-205.00K
Effective Tax Rate0.11
Enterprise Valuation
Diaceutics EV to EBITDA ratio is 34.01, with an EV/FCF ratio of -23.69.
EV to Sales2.93
EV to EBITDA34.01
EV to Free Cash Flow-23.69
EV to Operating Cash Flow144.86
Balance Sheet
Diaceutics has $10.38M in cash and marketable securities with $1.13M in debt, giving a net cash position of $9.25M billion.
Cash & Marketable Securities$10.38M
Total Debt$1.13M
Net Cash$9.25M
Net Cash Per Share$0.11
Tangible Book Value Per Share$0.29
Margins
Gross margin is 86.12%, with operating margin of -7.63%, and net profit margin of -5.30%.
Gross Margin86.12%
Operating Margin-7.63%
Pretax Margin-5.93%
Net Profit Margin-5.30%
EBITDA Margin8.62%
EBIT Margin-5.77%
Analyst Forecast
The average price target for Diaceutics is $183.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$183.80
Price Target Upside13.81% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast31.83%
EPS Growth Forecast46.59%